Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market [Yahoo! Finance]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Compass Therapeutics (CMPX) is back on investors' radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing treatment area. See our latest analysis for Compass Therapeutics. The latest focus on CTX-009 comes after a period where Compass Therapeutics' share price has been choppy in the short term, with a 30 day share price return of an 11.25% decline, but underpinned by stronger momentum over longer horizons, including a 9.86% year to date share price return and a 108.06% total shareholder return over the past year. If this biliary tract cancer story has caught your attention, it could be a good moment to widen the lens and look at 28 healthcare AI stocks as another source of ideas in cutting edge therapies. With Compass Therapeutics still loss making,
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics (CMPX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Compass Therapeutics (CMPX) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Compass Therapeutics (CMPX) had its "outperform" rating reaffirmed by Raymond James Financial, Inc..MarketBeat
- Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics Reports 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
CMPX
Earnings
- 3/5/26 - Beat
CMPX
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/13/26 - Form SCHEDULE
- CMPX's page on the SEC website